Atlas Trials

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

Clinical trial NCT05153135 · COMPLETED

Trial details

NCT number
NCT05153135
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Study type
OBSERVATIONAL
Metastatic Breast Cancer
Start date
2020-05-08
Primary completion
2020-07-31
Enrollment
4320

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.